These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. Siris ES, Lyles KW, Singer FR, Meunier PJ. J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018 [Abstract] [Full Text] [Related]
3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson A. Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324 [Abstract] [Full Text] [Related]
6. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH. J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843 [Abstract] [Full Text] [Related]
7. Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree. Good D, Busfield F, Duffy D, Lovelock PK, Kesting JB, Cameron DP, Shaw JT. J Bone Miner Res; 2001 Jan; 16(1):33-8. PubMed ID: 11149487 [Abstract] [Full Text] [Related]
8. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. Cremers SC, Eekhoff ME, Den Hartigh J, Hamdy NA, Vermeij P, Papapoulos SE. J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726 [Abstract] [Full Text] [Related]
9. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH. Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [Abstract] [Full Text] [Related]